Meeting
2019 Genitourinary Cancers Symposium
Prognostic significance of lactate dehydrogenase-5 expression in patients with prostate cancer treated with androgen deprivation therapy and androgen receptor axis-targeted agents.
Authors
Wataru Fukuokaya
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
Wataru Fukuokaya , Takahiro Kimura , Mariko Honda , Hiroyuki Inaba , Kosuke Iwatani , Mori Keiichiro , Shun Sato , Hiroyuki Takahashi , Shin Egawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 300)
DOI
10.1200/JCO.2019.37.7_suppl.300
Abstract #
300
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2016 Genitourinary Cancers Symposium
Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.
First Author: Derek R Wilke
Poster
2014 Genitourinary Cancers Symposium
Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: Two-and-a-half years' follow-up.
First Author: Patricia A. Parker
Poster
2024 ASCO Genitourinary Cancers Symposium
Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.
First Author: Soumyajit Roy